BG
Last reporting period 30 Sep, 2023
Updated 18 Sep, 2024
Last price
—
Market cap $B
0.008
Exchange
XNAS - Nasdaq
-43 %
Last period ROE
What is ROE ?
The return on equity ratio shows how much net profit a company earns per unit of equity. To calculate the company's rating, the return on equity adjusted for the average level of financial leverage for 3 years is taken into account. The value of 20% is the benchmark for Eyestock Rating calculation.
See also BioNexus Gene
Company Analysis
BGLC valuation, rating, competitors, insights and company profile
Eyestock Rating
BGLC financial analysis by Eyestock methodology
Valuation
BGLC valuation using historical relative method
Statements
BGLC Income Statements, Balance Sheet and Cash Flow Statements
Dividends
BGLC dividend yield and annual dividend
The return on equity ratio shows how much net profit a company earns per unit of equity. To calculate the company's rating, the return on equity adjusted for the average level of financial leverage for 3 years is taken into account. The value of 20% is the benchmark for Eyestock Rating calculation.
BioNexus Gene`s ROE for the last twelve months ended 2023-09-30 is -43 %
